4.2 Review

The Evolution of Adjuvant Therapy in the Treatment of Early-Stage Colon Cancer

Journal

CLINICAL COLORECTAL CANCER
Volume 10, Issue 4, Pages 218-226

Publisher

CIG MEDIA GROUP, LP
DOI: 10.1016/j.clcc.2011.10.001

Keywords

Adjuvant chemotherapy; Bevacizumab; Biomarkers; Cetuximab; Elderly; Fluoropyrimidines; Oxaliplatin; Phase III; Stage II colon cancer; Stage III colon cancer

Categories

Funding

  1. Sanofi
  2. Roche
  3. Merck-Serono

Ask authors/readers for more resources

Adjuvant treatment of colon cancer, one of the most common malignancies, is an important issue in oncology. This article describes the development of adjuvant therapy and how the 2 major evolution steps, the successes of fluoropyrimidines, and then of oxaliplatin, have been achieved, Problems and failures, such as those of targeted therapies, also are addressed to help us to overcome their limitations. Special situations, such as stage II disease and an elderly population in which adjuvant chemotherapy is still controversial, are reviewed from the clinician perspective. The synthesis of these data allows us to conceive a future development focused on translational research. Clinical Colorectal Cancer, Vol. 10, No. 4, 218-26 (C) 2011 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available